Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12563659 | 0.84 | HTR2C (0.40) | CYP19A1HTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL1944621 | 0.82 | HTR2C (0.44) | CYP19A1HTR2CMEN1KMT2AUSP2 | |
| SCHEMBL1945261 | 0.81 | HTR2C (0.38) | CYP19A1HTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL1945260 | 0.81 | HTR2C (0.38) | CYP19A1HTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL7501162 | 0.79 | CYP19A1 (0.45) | CYP19A1HTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL7969548 | 0.79 | CYP19A1 (0.45) | CYP19A1HTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL12539690 | 0.77 | CFTR (0.69) | CYP19A1CFTRGOPCKMT2AALDH1A1 | |
| SCHEMBL8088303 | 0.75 | GAA (0.53) | CYP19A1HTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL10725754 | 0.72 | CYP19A1 (0.52) | CYP19A1HTR2CMEN1KMT2AUSP2 | |
| SCHEMBL512007 | 0.71 | CYP19A1 (0.48) | CYP19A1HTR2CMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507215-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067219-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | PTGDR2, PTGDR, TBXA2R | CYP19A1 219/4885CFTR 2667/4885GOPC 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.